Impax releases generic version of dutasteride capsules, 0.5 mg

Download PDF Copy

Editorial Checklist

Reviewed

Impax Laboratories, Inc.Nov 24 2015

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg. The Company immediately initiated commercialization activities through its generic division. This is the 13^th generic product launched in 2015 by Impax's generic division.

According to IMS Health (NSP), U.S. brand and generic sales of dutasteride capsules, 0.5 mg were approximately $457 million for the 12 months ending in September 2015.

Source:

Impax Laboratories, Inc.

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Mouse study confirms early inflammation in hereditary paralysis condition

Mouse study confirms early inflammation in hereditary paralysis condition

Genetic susceptibility to schizophrenia associated with thinner retinas

Genetic susceptibility to schizophrenia associated with thinner retinas

Survey reveals diverse practices in thoracic sympathetic surgery across Europe

Survey reveals diverse practices in thoracic sympathetic surgery across Europe

Shingles vaccine eligibility lowers dementia risk in older adults

Shingles vaccine eligibility lowers dementia risk in older adults

New study explores link between gut microbiome and autism spectrum disorder

New study explores link between gut microbiome and autism spectrum disorder

Study illuminates a general principle of neural processing in the brain’s serotonin system

Study illuminates a general principle of neural processing in the brain’s serotonin system

Engineered brain cells offer new hope for treating Alzheimer's

Engineered brain cells offer new hope for treating Alzheimer's

Study shows brain estrogen directly regulates appetite in mice

Study shows brain estrogen directly regulates appetite in mice

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New approach may prevent neurotoxic protein aggregates in ALS